Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials

BACKGROUND: Metastatic high-grade neuroendocrine neoplasms (G3NENs) have limited treatment options after progression on platinum-based therapy. We addressed the role of Pembrolizumab in patients with previously treated metastatic G3NENs. METHODS: Two open-label, phase 2 studies enrolled patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Vijayvergia, Namrata, Dasari, Arvind, Deng, Mengying, Litwin, Samuel, Al-Toubah, Taymeyah, Alpaugh, R. Katherine, Dotan, Efrat, Hall, Michael J., Ross, Nicole M., Runyen, Melissa M., Denlinger, Crystal S., Halperin, Daniel M., Cohen, Steven J., Engstrom, Paul F., Strosberg, Jonathan R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188798/
https://www.ncbi.nlm.nih.gov/pubmed/32152503
http://dx.doi.org/10.1038/s41416-020-0775-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188798/
https://www.ncbi.nlm.nih.gov/pubmed/32152503
http://dx.doi.org/10.1038/s41416-020-0775-0

Ejemplares similares